Top 10 Coronavirus Treatment Companies | Best Healthcare Solutions

Coronavirus Treatment Market Overview

COVID-19 or Coronavirus treatment companies have advanced with key approaches including vaccines, antiviral drugs, monoclonal antibodies, and supportive care. Vaccines like Pfizer-BioNTech and Moderna have significantly reduced severe cases.

Antivirals such as Remdesivir, Molnupiravir, and Paxlovid help limit viral replication and severe outcomes, while monoclonal antibodies like Bamlanivimab offer early intervention for high-risk patients.

Supportive care, including oxygen, corticosteroids, and anticoagulants, remains crucial for severe cases. Ongoing research is focusing on new treatments like inhaled antivirals and immune modulators.

Market Drivers

The global coronavirus treatment market has been driven by the ongoing spread of COVID-19, new variants, and increased demand for effective therapies.

Government and healthcare investments, along with rapid vaccine advancements, have accelerated treatment availability.

Early intervention with antivirals and monoclonal antibodies has become crucial, while the rise of Long COVID-19, evolving treatment protocols, and regulatory approvals have further boosted market growth. Global collaboration and public-private partnerships have expanded treatment options and accessibility.

Market Size

The global pulmonary drug delivery systems market is expected to reach USD 97.8 billion by 2033, growing at a 5.7% CAGR.

List of Major Companies

These are the top ten companies operating in the Coronavirus Treatment Market:

• Moderna
• Merck
• GSK
• Novartis
• Johnson-n-Johnson
• Bristol-Myers-Squibb
• Sanofi
• Pfizer
• AstraZeneca
• AbbVie

Moderna

Company Overview

About Moderna

Moderna, Inc. is a leading biotech company known for its mRNA-based COVID-19 vaccine, mRNA-1273, which was one of the first to gain emergency use authorization from the FDA.

Initially focused on the Coronavirus Treatment companies/sector, Moderna has expanded its mRNA platform to include treatments for cancer and respiratory infections.

The company has strengthened its position through strategic partnerships, such as with Merck for cancer therapies, and is scaling up production capacity.

With substantial funding from government contracts and private investments, Moderna is advancing its R&D efforts and diversifying its pipeline, positioning itself for future growth beyond Coronavirus treatment companies.

Geographical Presence

Moderna, Inc., a biotechnology company specializing in mRNA therapeutics, has a global presence, with operations spanning North America, Europe, Asia, Latin America, Africa, and the Middle East.

Headquartered in Cambridge, Massachusetts, Moderna plays a leading role in vaccine development, notably through its COVID-19 vaccine, and has established manufacturing and R&D facilities across the U.S. and Europe.

The company has strategic partnerships with governments and health organizations worldwide, including collaborations in Japan, South Korea, Brazil, and South Africa.

With ongoing expansions in manufacturing capacity and clinical trials, Moderna aims to strengthen its global footprint and continue advancing mRNA-based vaccines and therapies for various health conditions.

Recent Developments

• In October 2024, Merck and Moderna launched the INTerpath-009 Phase 3 trial to evaluate V940 (mRNA-4157) with KEYTRUDA® as adjuvant treatment for resectable Stage II–IIIB (N2) non-small cell lung cancer patients who did not respond to neoadjuvant KEYTRUDA and chemotherapy.
• In September 2024, Moderna and Cenra Inc. formed a joint agreement to co-promote Moderna’s mRNA respiratory vaccine portfolio, including the COVID-19 vaccine Spikevax®, in Taiwan.

Merck

Company Overview

About Merck

Merck & Co., Inc. has been active in developing treatments for COVID-19, notably through the antiviral pill molnupiravir, which received Emergency Use Authorization from the U.S.

Food and Drug Administration in December 2021 for treating mild to moderate COVID-19 in high-risk adults.  In recent developments, Merck has expanded its oncology portfolio by acquiring Harpoon Therapeutics for $680 million in January 2024, enhancing its cancer treatment offerings.

Additionally, in April 2024, Merck completed the acquisition of Abceutics for $208 million, further strengthening its position in the pharmaceutical industry. These strategic moves reflect Merck’s commitment to advancing its therapeutic capabilities across various medical fields. 

Geographical Presence

Merck & Co., Inc. operates globally, with a significant presence across various regions. In 2023, the company generated $28.5 billion in the United States, $13.3 billion in Europe, the Middle East, and Africa, $6.8 billion in China, $3.2 billion in Japan, and substantial revenue from other regions like Latin America and Asia Pacific.

Its diverse geographical footprint includes strong operations in North and South America, Europe, and Asia, highlighting its commitment to providing healthcare solutions worldwide.

Recent Developments

• In November 2024, Merck announced positive results from the Phase 3 ZENITH study of WINREVAIR (sotatercept-csrk) in high-risk pulmonary arterial hypertension (FC III or IV) adults.
• In December 2021, Merck and Ridgeback Biotherapeutics announced FDA Emergency Use Authorization for molnupiravir (MK-4482, EIDD-2801) to treat mild to moderate COVID-19 in high-risk adults.

GSK

Company Overview

About GSK

GSK has been actively developing Coronavirus treatment companies, including its collaboration with Vir Biotechnology on sotrovimab, a monoclonal antibody therapy authorized by the FDA in May 2021.

Recently, GSK restructured its partnership with CureVac, acquiring global rights to develop mRNA vaccines for influenza and COVID-19 in a deal worth up to €1.45 billion.

Additionally, GSK partnered with Touchlight to leverage its DNA technology for accelerating mRNA vaccine production for seasonal epidemics and pandemics, further strengthening its position in COVID-19 treatment development.

Geographical Presence

GSK plc, a global leader in pharmaceuticals and biotechnology, operates in over 100 countries worldwide. Its geographical presence spans across Africa, the Middle East, the Americas, Asia Pacific, and Europe.

The company has significant operations in regions including South Africa, Saudi Arabia, the United States, Brazil, China, Japan, India, and various European nations such as Germany, France, and the UK.

This wide-reaching footprint allows GSK to address diverse healthcare needs across different markets, enhancing its ability to deliver impactful healthcare solutions globally.

Recent Development

• In November 2024, GSK announced that the FDA has accepted the BLA for Blenrep (belantamab mafodotin) in combination with BorDex or PomDex for treating multiple myeloma patients with prior therapy.
• In May 2021, GSK and Vir Biotechnology announced that the FDA granted Emergency Use Authorization (EUA) for sotrovimab (VIR-7831), a monoclonal antibody for treating mild-to-moderate COVID-19 in high-risk adults and pediatric patients aged 12 and older.

Novartis

Company Overview

About Novartis

Novartis AG has actively contributed to Coronavirus treatment companies development, leveraging its expertise in immunology and respiratory diseases.

The company has repurposed existing therapies and partnered with other biopharma firms to improve vaccine access and research monoclonal antibodies for COVID-19 treatment.

In 2023, Novartis acquired Chinook Therapeutics to strengthen its focus on kidney disease, a common comorbidity in severe COVID-19 cases.

Additionally, Novartis is expanding its respiratory and immunology portfolio, which may aid in post-viral recovery and long-term management, reinforcing its commitment to advancing healthcare solutions in response to the pandemic.

Geographical Presence

Novartis AG, headquartered in Basel, Switzerland, has a significant global presence, operating in over 150 countries.

Key markets include North America, particularly the U.S. and Canada, Europe with a strong presence in Germany, France, and the UK, and Asia-Pacific, including Japan, China, and India.

The company is also active in Latin America, notably Brazil and Mexico, as well as in the Middle East and Africa, with major operations in South Africa and the Gulf region. Novartis’ research and development centers are strategically located in Switzerland, the U.S., and India.

Its diverse global footprint enables the company to leverage both innovative therapies and affordable generics, maintaining leadership across therapeutic areas such as oncology, ophthalmology, and immunology.

Recent Development

• In September 2024, Novartis sold Worldwide Rights to DESFERAL (deferoxamine) to MITEM Pharma.
• In July 2023, Novartis acquired DTx Pharma, a San Diego biotech focused on siRNA therapies for neuroscience using its FALCON platform.

Johnson-n-Johnson

Company Overview

About Johnson & Johnson

Johnson & Johnson (J&J) played a pivotal role in the Coronavirus treatment companies’ response, notably through its single-dose vaccine, developed by its Janssen division, which received emergency use authorization from the U.S. FDA in early 2021.

The vaccine, based on a viral vector platform, was crucial in regions with limited cold storage capacity. J&J also repurposed existing treatments to address COVID-19 complications.

In 2023, J&J strengthened its healthcare position by acquiring Abiomed, a leader in heart pump technology, and increased investment in vaccine production to enhance global access. These efforts solidify J&J’s leadership in both pandemic response and healthcare innovation.

Geographical Presence

Johnson & Johnson (J&J) operates in over 60 countries and sells its products in more than 175 nations, with a strong presence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The company’s U.S. market remains its largest, while key European markets include the UK, Germany, and France. In Asia, J&J has a significant footprint in China, India, and Japan, driven by rising healthcare demands.

Latin America, particularly Brazil and Mexico, contributes notably to its consumer health and medical device sales, while Africa and Eastern Europe represent emerging growth regions.

With over 250 manufacturing sites and extensive R&D hubs globally, J&J continues to leverage its geographical diversification to capture new opportunities and expand market access.

Recent Developments

• In November 2024, the FDA granted Breakthrough Therapy designation to J&J’s nipocalimab for Sjögren’s disease.
• In November 2024, Johnson & Johnson submitted regulatory applications to the FDA and EMA for new DARZALEX indications in the U.S. and EU.

Bristol-Myers-Squibb

Company Overview

About Bristol Myers Squibb

Bristol Myers Squibb (BMS) has played an active role in combating COVID-19, leveraging its expertise in immunology and oncology to explore potential treatments.

The company developed BMS-986207, a monoclonal antibody, to treat moderate-to-severe COVID-19 cases. BMS also partnered with other organizations to advance antiviral research and support vaccine efforts.

In 2021, BMS expanded its portfolio with the acquisition of MyoKardia, a leader in cardiovascular treatments.

Additionally, in 2023, BMS reported positive results for its immunotherapy drug Opdivo, in combination with other therapies, for COVID-19 complications.

The company has also enhanced its manufacturing and distribution capabilities to support global access to vaccines and therapeutics.

Geographical Presence

Bristol Myers Squibb (BMS) has a strong global presence, with key operations in North America, Europe, Asia-Pacific, and emerging markets.

Headquartered in the U.S., the company has research, development, and manufacturing facilities across multiple states.

In Europe, it maintains offices and research centers in the UK, Germany, and Switzerland. BMS is also expanding in Asia, with operations in Japan, China, India, and partnerships in South Korea and Australia.

The company is growing its footprint in emerging markets, including Latin America, the Middle East, and Africa, focusing on both commercial expansion and healthcare access. This global reach allows BMS to address diverse market needs and capitalize on growth opportunities.

Recent Developments

• In November 2024, BMS announced EMA’s CHMP recommendation of Opdivo® plus Yervoy® for first-line MSI-H/dMMR metastatic colorectal cancer.
• In November 2024, BMS announced EMA’s CHMP recommendation to approve repotrectinib for ROS1-positive NSCLC and NTRK gene fusion tumors in adults and pediatric patients (12+).

Sanofi

Company Overview

About Sanofi

Sanofi S.A. has been a key player in the global Coronavirus treatment companies’ response, focusing on vaccine development and therapeutic interventions.

In collaboration with GSK, it developed a protein-based COVID-19 vaccine, which received conditional approvals after successful clinical trials.

The company also repurposed its rheumatoid arthritis drug, Kevzara, for emergency use in severe COVID-19 cases.

In addition, Sanofi strengthened its portfolio through the 2023 acquisition of Provention Bio, a company specializing in autoimmune diseases, which enhances its immunology offerings.

The company has also invested in expanding vaccine production and improving global access, while continuing to explore treatments for long-term COVID effects, underscoring its commitment to pandemic preparedness.

Geographical Presence

Sanofi S.A., a global biopharmaceutical company based in Paris, operates in over 100 countries, with a strong presence in key markets across Europe, North America, Asia-Pacific, Latin America, and the Middle East & Africa.

In Europe, it maintains a significant market share, especially in France, Germany, and the UK. In North America, the U.S. is a major market, particularly for its diabetes and oncology products.

The company is expanding rapidly in emerging markets like China, India, and Brazil, focusing on vaccines, diabetes care, and rare diseases.

Sanofi also has R&D and manufacturing facilities across multiple regions, including the U.S., France, and China, supporting its global portfolio of pharmaceuticals, vaccines, and consumer health products.

Recent Developments

• In November 2024, the FDA accepted Dupixent’s sBLA for treating chronic spontaneous urticaria (CSU) in patients aged 12+ not controlled by H1 antihistamines.
• In November 2024, EMA’s CHMP recommended Sarclisa with VRd for newly diagnosed multiple myeloma in adults ineligible for stem cell transplant.

Pfizer

Company Overview

About Pfizer

Pfizer Inc. has played a key role in the global response to Coronavirus treatment companies, developing the mRNA-based vaccine Comirnaty in partnership with BioNTech, which was one of the first to receive emergency use authorization.

Pfizer also introduced Paxlovid, an oral antiviral treatment for high-risk COVID-19 patients, which has been essential in reducing hospitalizations.

In 2023, Pfizer expanded its portfolio by acquiring Trillium Therapeutics, enhancing its oncology pipeline. The company continues to invest in vaccine development, including addressing emerging COVID-19 variants, reinforcing its leadership in pandemic response and biopharmaceutical innovation.

Geographical Presence

Pfizer Inc. has a vast global presence, with operations in North America, Europe, Asia, Latin America, the Middle East, Africa, and emerging markets.

Its U.S. headquarters serves as a central hub, with significant R&D and manufacturing facilities across the country, while Canada, the UK, Germany, France, and Italy contribute to its strong European presence.

In Asia, China, India, and Japan are key markets, driven by rising healthcare demands. Latin America, particularly Brazil and Mexico, is a growing region for Pfizer, alongside expanding operations in South Africa, Saudi Arabia, and the UAE.

With over 60 manufacturing sites worldwide and R&D centers in key locations like the U.S., Germany, and China, Pfizer leverages its global footprint to drive innovation and meet diverse healthcare needs.

Recent Development

• In November 2024, Pfizer announced EU approval of HYMPAVZI™ (marstacimab) for bleeding prophylaxis in patients 12+ with severe hemophilia A or B, without FVIII or FIX inhibitors.
• In October 2023, Pfizer announced FDA approval of ABRYSVO® (RSVpreF) for preventing RSV-related lower respiratory tract disease in at-risk individuals aged 18-59.

AstraZeneca

Company Overview

About AstraZeneca

AstraZeneca played a key role in the global Coronavirus treatment companies response through the development of its vaccine, Vaxzevria, in collaboration with the University of Oxford.

Using viral vector technology, the vaccine has been widely distributed, especially in lower- and middle-income countries.

The company has also developed monoclonal antibody treatments to reduce severe symptoms in high-risk COVID-19 patients.

In 2023, AstraZeneca expanded its oncology portfolio by acquiring U.S.-based biotech firm TeneoOne, which specializes in cancer therapies.

Additionally, the company has invested in increasing vaccine production and access, particularly in low-income regions, reinforcing its commitment to public health and its leadership in biopharmaceutical innovation.

Geographical Presence

AstraZeneca plc operates in over 100 countries, with a strong presence in North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Its largest market is the United States, where it also has significant R&D and manufacturing operations.

In Europe, the company maintains its global headquarters in the UK and has R&D centers in Sweden. AstraZeneca is expanding rapidly in Asia-Pacific, with a notable presence in China, Japan, and India, and is increasingly focused on emerging markets like Brazil, Mexico, and Russia.

The company’s global footprint is supported by manufacturing facilities and R&D hubs in key regions, ensuring widespread access to its medicines across various therapeutic areas, including oncology, cardiovascular, and respiratory diseases.

Recent Developments

• In November 2024, AstraZeneca declared an investment of $3.5 billion in the U.S. by 2026 to expand research and manufacturing, including $2 billion to create 1,000+ high-skilled jobs.
• In November 2024, the CAPItello-281 trial showed that AstraZeneca’s Truqap with abiraterone and ADT significantly improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.

AbbVie

Company Overview

About AbbVie

AbbVie Inc. has actively contributed to the Coronavirus treatment companies response by researching treatments for severe symptoms and long-term effects, although it did not develop a vaccine.

The company explored its antiviral drug Kaletra (lopinavir/ritonavir) for early-stage infections, but it was ineffective in large trials.

AbbVie also focused on long COVID research, leveraging its expertise in immunology and inflammation. In 2020, AbbVie strengthened its portfolio with the acquisition of Allergan, expanding its presence in aesthetics and eye care.

The company continues to invest in its immunology and oncology pipelines, particularly to address post-viral complications, positioning itself for continued growth in the evolving healthcare landscape.

Geographical Presence

AbbVie Inc. is a global biopharmaceutical company with a significant geographical presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Headquartered in North Chicago, Illinois, AbbVie operates R&D and manufacturing facilities in key regions, including the U.S., Canada, the UK, Germany, and Japan.

The company has a strong market presence in emerging economies such as China, India, and Brazil, and has expanded its portfolio through strategic acquisitions like Allergan.

AbbVie’s global footprint is supported by a robust supply chain, regulatory partnerships, and a focus on key therapeutic areas such as immunology, oncology, and neuroscience.

Recent Developments

• In October 2024, AbbVie’s VYALEV, a 24-hour infusion therapy for motor fluctuations in advanced Parkinson’s disease, was approved by the FDA.
• In December 2023, AbbVie acquired Cerevel Therapeutics, expanding its neuroscience portfolio with treatments for schizophrenia, Parkinson’s, and mood disorders.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF